Zenosense Inc (OTCMKTS:ZENO): Catching Up On The Latest Releases

When we covered Zenosense Inc (OTCMKTS:ZENO) back at the start of February as part of this piece, the company had just run up to the tune of 300% in a week on what looked to be no real developments. When that sort of thing happens, it's generally because someone knows (or is expecting) something that's not yet hit wider markets, or that the stock is getting pumped. After a bit of digging, we couldn’t find anyone pumping the company, and rested on the former suggestion – that something is coming, and that someone somewhere was loading up in anticipation of this.Since our coverage, Zenosense has continued to strengthen, albeit not to the tune of 300%, and this, yet again, reinforces the suggestion that this move is supported by hidden fundamental developments, as opposed to promotional cash.Over the last few weeks, a few announcements have hit press that offer a bit of insight into what we might expect near term, and in turn, what the accumulation might be anticipating. Here's a look at each, and what they mean going forward.For those new to the company, Zonesense is a medical device company working to develop a diagnostic technology called the MIDS Cardiac Device. It's designed to improve on the current detection technology that physicians use to determine a patient's cardiac risk.When a patient has some type of cardiac event (heart attack, cardiac tension, that sort of thing) a protein called troponin is released into their blood. The more serious the event, the higher the level of troponin released. Current available technology can detect troponin, but only when it's in clumps, and only using a pretty large blood draw. With the MIDS Cardiac Device, Zenosense is trying to develop a device that can detect troponin in tiny amounts, and from a blood sample similar in volume to the sample taken by diabetes patients to measure blood glucose (i.e. a pinprick).It could revolutionize the way physicians detect cardiac risk, and as such, might not only make a real difference in healthcare, but could be a real money saver for the healthcare system as a result.Anyway, the tech is in the early stages of development, and the recent developments relate to the progress of this program. Specifically, they relate to some bench rigs designed to output results that will compliment the development of the final product. Test results from the first rig came back on March 10, and reportedly resulted in excellent linearity of average system output signal against sample drop volume, as well as high levels of output signal, even at the smallest sample volumes. Further communication on the back of this test output detailed the construction of the second bench reader, which will take the results from the first read and use them to facilitate the final design of what’s called a hybrid strip, which readers should think of as a sort of prototype (although it's a little more advanced that prototype) version of the final strip that's going to be used in the test system – called the Lab-On-Chip.So that's the device progress.In the most recent announcement, Zenosense detailed the bringing on board of an entity called Future Diagnostics Solutions B.V. as a development partner. At core, it looks as though relationship between the two companies is going to be one of designer/consulting. Future has a facility that Zenosense can use to develop its assay (or future can develop the assay in house, based on Zenosense specs – probably the more likely scenario) and this assay can then tie in with the above mentioned Lab-On-Chip final product.Bottom line here is that this technology is still very young, and it's not going to start generating the company revenues until at least mid 2018, at the earliest, but it could be a real game changer if and when it hits shelves. As such, we're probably looking at some degree of dilution between now and revenue collection (probably is an understatement here) but if the MIDS device hits shelves, there's a $1.4 billion cardiac testing market waiting to be targeted.We will be updating our subscribers as soon as we know more. For the latest updates on ZENO, sign up below!Disclosure: We have no position in ZENO and have not been compensated for this article.